181 related articles for article (PubMed ID: 34249750)
1. TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma.
Bao S; Jiang X; Jin S; Tu P; Lu J
Front Oncol; 2021; 11():694145. PubMed ID: 34249750
[TBL] [Abstract][Full Text] [Related]
2. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
3. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
[TBL] [Abstract][Full Text] [Related]
5. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
6. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Gastroenterology; 2024 Feb; ():. PubMed ID: 38417530
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
13. Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.
Minguillón J; Morancho B; Kim SJ; López-Botet M; Aramburu J
J Leukoc Biol; 2005 May; 77(5):748-58. PubMed ID: 15716327
[TBL] [Abstract][Full Text] [Related]
14. Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
Lin GH; Wang J; Li SH; Wang J; Xu L; Li SP
Chin J Cancer; 2010 Apr; 29(4):403-7. PubMed ID: 20346216
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma.
Yuen MF; Hughes RD; Heneghan MA; Langley PG; Norris S
Cancer; 2001 Oct; 92(8):2136-41. PubMed ID: 11596030
[TBL] [Abstract][Full Text] [Related]
16. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
[TBL] [Abstract][Full Text] [Related]
17. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
Ji GZ; Wang XH; Miao L; Liu Z; Zhang P; Zhang FM; Yang JB
World J Gastroenterol; 2006 Jan; 12(4):644-8. PubMed ID: 16489684
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.
Raziorrouh B; Ulsenheimer A; Schraut W; Heeg M; Kurktschiev P; Zachoval R; Jung MC; Thimme R; Neumann-Haefelin C; Horster S; Wächtler M; Spannagl M; Haas J; Diepolder HM; Grüner NH
Gastroenterology; 2011 Oct; 141(4):1422-31, 1431.e1-6. PubMed ID: 21763239
[TBL] [Abstract][Full Text] [Related]
19. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
20. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma.
Zhang H; Ozaki I; Mizuta T; Hamajima H; Yasutake T; Eguchi Y; Ideguchi H; Yamamoto K; Matsuhashi S
Oncogene; 2006 Oct; 25(45):6101-12. PubMed ID: 16682950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
